How do sing might influence the conclusion in an antipsychotic polypharmacy effectiveness trial

American Journal of Psychiatry

Volumn 168, Issue 10, 2011, Pages 1117-

  Baandrup, Lone ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL PROTOCOL; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; OUTCOME ASSESSMENT; PHYSICIAN; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA; FEMALE; MALE; NOTE;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; POLYPHARMACY; SCHIZOPHRENIA;

EID: 80054795788     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.11050751     Document Type: Letter

References (1)

1. Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH, The Schizophrenia Trials Network: Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168:702-708